Cataplexy clinical trials

The registry lists 31 studies for Cataplexy across more than 10 countries. 5 are recruiting or about to start. 19 of them are mainly about Cataplexy (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-03.

Get an email when these change. Save the Cataplexy studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 25
Recruiting: 4
Not yet recruiting: 1
Status unknown: 1

Phase

Phase 3: 19
Phase 2: 5
Phase 1: 1

Where

United States: 16
Canada: 11
France: 9
Switzerland: 5
Spain: 4
Australia: 4

Who runs them

Bioprojet (5) · Axsome Therapeutics, Inc. (3) · Avadel (2) · AstraZeneca (2) · Cephalon (2) · Alkermes, Inc. (2) · Suven Life Sciences Limited (2) · Jazz Pharmaceuticals (1)

What is being tested here

Drugs under test in Cataplexy studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Samelisant	1	1	2
Mazindol	1	1	1
HBS-301	1	1	1
Pitolisant	0	5	5
Reboxetine	0	2	3
Modafinil	0	2	3
FT218	0	2	2
Sodium Oxybate	0	2	2
Oxybate	0	2	2
Disufenton sodium	0	1	2

Drug classes tested here Stimulants 1 open

Coming up

5phase 3 studies under way

4studies finish main data collection within a yearall phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 4, phase 3 first

May 2027A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 · Phase 3 · Alkermes, Inc.
Sep 2027A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence · Phase 3 · Centessa Pharmaceuticals (UK) Limited
Oct 2027A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy · Phase 3 · Harmony Biosciences Management, Inc.
Nov 2027A Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy (AWAKE) · Phase 3 · Suven Life Sciences Limited

Who these studies take

Of the 4 Cataplexy studies recruiting now, 2 (50%) set no upper age limit and 2 (50%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 4
Age	Women	Men
10	0 (0%)	0 (0%)
18	4 (100%)	4 (100%)
30	4 (100%)	4 (100%)
40	4 (100%)	4 (100%)
50	4 (100%)	4 (100%)
65	4 (100%)	4 (100%)
75	2 (50%)	2 (50%)
85	2 (50%)	2 (50%)

Across all 31 studies, recruiting or not: 35% stop at 75 or younger and 16% at 65; 35% take children; 0% are for women only and 0% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 31 of 31. search them.